Registry for studying Transthyretin Amyloid Cardiomyopathy in Thailand

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to longitudinally study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Thailand. By collecting detailed data on both symptomatic and asymptomatic patients, the investigators hope to enhance understanding of the disease and develop early screening programs for at-risk individuals. The findings will also support epidemiological studies and raise awareness among healthcare providers about this condition, especially as amyloid-specific therapies become available in the region.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years.
* All patients diagnosed with ATTR-CM (Transthyretin cardiomyopathy) who have either symptomatic or asymptomatic must have evidence of cardiac involvement by echocardiogram as defined by left ventricle wall thickness of ≥ 12 mm and with at least one of the following criteria:
* Positive scintigraphy by 99mTC-DPD \[99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mTC-PYP \[Pyrophosphate\] or 99mTC-HMDP \[hydroxymethylene diphosphate\] with Perugini grade ≥ 2 and/or H/CL (heart to contralateral lung) ratio \> 1.5
* Positive scintigraphy by 99mTC-DPD \[99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mTC-PYP \[Pyrophosphate\] or 99mTC-HMDP \[hydroxymethylene diphosphate\] with Perugini grade 1 and positive cardiac biopsy tissue confirmed which Congo red stain ≥ 4 sites
* Positive scintigraphy by 99mTC-DPD \[99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mTC-PYP \[Pyrophosphate\] or 99mTC-HMDP \[hydroxymethylene diphosphate\] with Perugini grade 1 with positive non-cardiac biopsy tissue confirmed by Congo red stain
* Abnormalities on CMR (Cardiac MRI) \[Subendocardium LGE (late gadolinium enhancement) and/or elevated native T1 value and/or increased extracellular volume (ECV \> 0.4)\] with positive non-cardiac and/or cardiac tissue biopsy confirmed by Congo red stain

Exclusion Criteria:

* Diagnosed with amyloidosis caused by proteins other than transthyretin (light chain Amyloidosis, etc.)
* Diagnosed with secondary amyloidosis

Where it's running

• Prince of Songkla University
  Songkhla, Thailand Recruiting
• Faculty of Medicine at Chulalongkorn University
  Bangkok, Thailand Not yet recruiting
• Faculty of Medicine Ramathibodi hospital, Mahidol University
  Bangkok, Thailand Not yet recruiting
• Faculty of Medicine Siriraj Hospital, Mahidol University
  Bangkok, Thailand Not yet recruiting
• Phramongkutklao Hospital
  Bangkok, Thailand Not yet recruiting
• Faculty of Medicine Chiang Mai University
  Chiang Mai, Thailand Not yet recruiting

Study contacts

• Principal investigator: Rungroj Krittayaphong, MD, FESC, FACC — Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University
• Study coordinator: Kanchalaporn Jirataiporn, B.N.S.
• Email: kanchalaporn.jir@mahidol.ac.th
• Phone: 0635153519

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoramidis in adults with transthyretin amyloid cardiomyopathy in France

  This is an observational study to see how acoramidis is used in everyday care for adults with ATTR‑CM in France and how it affects their quality of life and daily function.

  Recruiting Bayer · Many Locations · NCT07791160

• Acoramidis for transthyretin amyloid cardiomyopathy in routine care

  See how acoramidis works for adults with transthyretin amyloid cardiomyopathy (wild-type or variant) when given as part of regular clinical care.

  Recruiting at 17 sites Bayer · Multiple Locations and 16 other locations · NCT07235462

• Coramitug (NNC6019-0001) for heart failure from transthyretin amyloid cardiomyopathy

  This study tests whether coramitug (NNC6019-0001) can lower the risk of heart-related death and illness in adults with transthyretin amyloid cardiomyopathy (ATTR-CM) while they continue their usual heart medicines.

  Recruiting at 237 sites Phase 3 Novo Nordisk A/S · Phoenix, Arizona and 298 other locations · NCT07207811

• US benchmarking of heart and liver stiffness using shear wave ultrasound

  This project will test whether a new ultrasound device can measure heart and liver stiffness using shear wave velocity in people aged 60 or older with preserved or mildly reduced ejection fraction and left ventricular hypertrophy, with or without transthyretin amyloid cardiomyopathy, and in control subjects.

  Recruiting at 3 sites eMyosound SAS · Boston, Massachusetts and 2 other locations · NCT07215715

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• Investigating early signs of heart disease in specific genetic carriers

  This study is trying to find early signs of heart disease in people with a specific genetic mutation linked to a heart condition called amyloidosis to help catch the disease sooner.

  Recruiting at 3 sites University of Texas Southwestern Medical Center · New York, New York and 2 other locations · NCT05489549

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.